CA3114722A1 - Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use - Google Patents
Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use Download PDFInfo
- Publication number
- CA3114722A1 CA3114722A1 CA3114722A CA3114722A CA3114722A1 CA 3114722 A1 CA3114722 A1 CA 3114722A1 CA 3114722 A CA3114722 A CA 3114722A CA 3114722 A CA3114722 A CA 3114722A CA 3114722 A1 CA3114722 A1 CA 3114722A1
- Authority
- CA
- Canada
- Prior art keywords
- thieno
- trifluoromethyl
- alkyl
- pyridin
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862739405P | 2018-10-01 | 2018-10-01 | |
| US62/739,405 | 2018-10-01 | ||
| PCT/US2019/054085 WO2020072504A1 (en) | 2018-10-01 | 2019-10-01 | Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3114722A1 true CA3114722A1 (en) | 2020-04-09 |
Family
ID=68296740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3114722A Pending CA3114722A1 (en) | 2018-10-01 | 2019-10-01 | Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11098056B2 (https=) |
| EP (1) | EP3861000A1 (https=) |
| JP (1) | JP7545979B2 (https=) |
| KR (1) | KR102903997B1 (https=) |
| CN (1) | CN113423711B (https=) |
| AU (1) | AU2019355870B2 (https=) |
| BR (1) | BR112021005914A2 (https=) |
| CA (1) | CA3114722A1 (https=) |
| CO (1) | CO2021005738A2 (https=) |
| IL (1) | IL281811B2 (https=) |
| MA (1) | MA53043B2 (https=) |
| MX (1) | MX2021003794A (https=) |
| SG (1) | SG11202102987VA (https=) |
| TW (1) | TWI821426B (https=) |
| WO (1) | WO2020072504A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202302565A (zh) * | 2021-02-19 | 2023-01-16 | 英商卡爾維斯塔製藥有限公司 | 酶抑制劑 |
| EP4483954A1 (en) * | 2023-06-29 | 2025-01-01 | Masarykova Univerzita | Substituted thieno [3,2-b]pyridines as inhibitors of protein kinases |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3763156A (en) * | 1970-01-28 | 1973-10-02 | Boehringer Sohn Ingelheim | 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines |
| US7375125B2 (en) * | 1999-08-04 | 2008-05-20 | Ore Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| MXPA02001160A (es) | 1999-08-04 | 2002-07-02 | Millennium Pharm Inc | Compuestos que se unen a los receptores para melanocortina-4, y metodo de uso de estos. |
| FR2821356A1 (fr) * | 2001-02-23 | 2002-08-30 | Cerep | Nouveaux derives d'arylcarbamates et d'arylurees, preparations et utilisations |
| EP3109249A1 (en) * | 2007-11-15 | 2016-12-28 | YM BioSciences Australia Pty Ltd | N-containing heterocyclic compounds |
| MX2011008276A (es) * | 2009-02-06 | 2011-12-14 | Elan Pharm Inc | Inhibidores de quinasa jun n-terminal. |
| JP2014511391A (ja) * | 2011-03-07 | 2014-05-15 | フォンダッツィオーネ・テレソン | Ｔｆｅｂリン酸化阻害剤およびその使用 |
| ES2928714T3 (es) * | 2015-01-16 | 2022-11-22 | Massachusetts Gen Hospital | Compuestos para mejorar el empalme del ARNm |
| JP7114076B2 (ja) | 2015-12-22 | 2022-08-08 | シャイ・セラピューティクス・エルエルシー | がん及び炎症性疾患の処置のための化合物 |
| SG11201809693SA (en) * | 2016-05-05 | 2018-11-29 | Lysosomal Therapeutics Inc | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| WO2017214505A1 (en) * | 2016-06-10 | 2017-12-14 | Biomarin Pharmaceutical Inc. | Ceramide galactosyltransferase inhibitors for the treatment of disease |
| MY193511A (en) * | 2016-11-02 | 2022-10-17 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors |
| WO2018118838A1 (en) * | 2016-12-20 | 2018-06-28 | Biomarin Pharmaceutical Inc. | Ceramide galactosyltransferase inhibitors for the treatment of disease |
| EP3619209A1 (en) * | 2017-05-04 | 2020-03-11 | Glenmark Pharmaceuticals S.A. | Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors |
| JP7514005B2 (ja) | 2017-06-21 | 2024-07-10 | シャイ・セラピューティクス・エルエルシー | がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物 |
-
2019
- 2019-10-01 SG SG11202102987VA patent/SG11202102987VA/en unknown
- 2019-10-01 EP EP19791011.0A patent/EP3861000A1/en active Pending
- 2019-10-01 CA CA3114722A patent/CA3114722A1/en active Pending
- 2019-10-01 CN CN201980076707.1A patent/CN113423711B/zh active Active
- 2019-10-01 AU AU2019355870A patent/AU2019355870B2/en active Active
- 2019-10-01 IL IL281811A patent/IL281811B2/en unknown
- 2019-10-01 KR KR1020217013167A patent/KR102903997B1/ko active Active
- 2019-10-01 WO PCT/US2019/054085 patent/WO2020072504A1/en not_active Ceased
- 2019-10-01 US US16/590,027 patent/US11098056B2/en active Active
- 2019-10-01 BR BR112021005914-8A patent/BR112021005914A2/pt unknown
- 2019-10-01 MA MA53043A patent/MA53043B2/fr unknown
- 2019-10-01 JP JP2021542086A patent/JP7545979B2/ja active Active
- 2019-10-01 MX MX2021003794A patent/MX2021003794A/es unknown
- 2019-10-01 TW TW108135781A patent/TWI821426B/zh active
-
2021
- 2021-04-29 CO CONC2021/0005738A patent/CO2021005738A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL281811B2 (en) | 2025-03-01 |
| JP2022508523A (ja) | 2022-01-19 |
| US11098056B2 (en) | 2021-08-24 |
| MX2021003794A (es) | 2021-09-08 |
| BR112021005914A2 (pt) | 2021-06-29 |
| AU2019355870B2 (en) | 2023-11-16 |
| SG11202102987VA (en) | 2021-04-29 |
| MA53043A1 (fr) | 2022-08-31 |
| TW202035419A (zh) | 2020-10-01 |
| IL281811A (en) | 2021-05-31 |
| EP3861000A1 (en) | 2021-08-11 |
| KR20210087033A (ko) | 2021-07-09 |
| AU2019355870A1 (en) | 2021-05-20 |
| IL281811B1 (en) | 2024-11-01 |
| MA53043B2 (fr) | 2024-05-31 |
| CN113423711B (zh) | 2024-03-15 |
| KR102903997B1 (ko) | 2025-12-26 |
| US20200102324A1 (en) | 2020-04-02 |
| WO2020072504A1 (en) | 2020-04-09 |
| TWI821426B (zh) | 2023-11-11 |
| CN113423711A (zh) | 2021-09-21 |
| CO2021005738A2 (es) | 2021-05-10 |
| JP7545979B2 (ja) | 2024-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9273057B2 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| EP3359541B1 (en) | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | |
| ES2548532T3 (es) | Compuestos de pirrolopirimidina como inhibidores de CDK4/6 | |
| KR20230040991A (ko) | Braf 분해제 | |
| KR20230028269A (ko) | 헌팅턴병을 치료하기 위한 htt 조절제 | |
| MX2014003612A (es) | Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso. | |
| US11319324B2 (en) | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | |
| EP3546458B1 (en) | ((pyridin-2-yl)-amino)pyrido[3,4-d]pyrimidine and ((pyridazin-3-yl)-amino)pyrido[3,4-d]pyrimidine derivatives as cdk4/6 inhibitors for treating e.g. rheumatoid arthritis, arteriosclerosis, pulmonary fibrosis, cerebral infarction or cancer | |
| US20240342292A1 (en) | Compounds for the Degradation of EGFR Kinase | |
| US20240109917A1 (en) | Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors | |
| ES3023544T3 (en) | Atm kinase inhibitors and compositions and methods of use thereof | |
| AU2019355870B2 (en) | Thieno[3,2-b]pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use | |
| RU2810928C2 (ru) | Ингибиторы уридин-5-дифосфат (udp) гликозилтрансферазы и способы их применения | |
| EP3008068B1 (en) | Tetraaza-cyclopenta[a]indenyl derivatives | |
| HK40082036A (en) | Atm kinase inhibitors and compositions and methods of use thereof | |
| HK40082036B (en) | Atm kinase inhibitors and compositions and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220826 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240917 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240917 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240917 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241007 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241022 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250113 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250515 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250515 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250801 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250829 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250904 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250904 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED Effective date: 20251231 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251231 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT Effective date: 20260225 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260225 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260225 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260225 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260225 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260226 |